The baseline characteristics of patients who enrolled in these two Phase 3 trials suggest that individuals living with rare genetic diseases of obesity, such as POMC or LEPR deficiency, have an impaired, and in some cases severely impaired, QOL. This evidence concerns the gene POMC and obesity due to melanocortin 4 receptor deficiency.